Cipla Limited has informed the Exchange regarding a press release dated July 25, 2025, titled "Press Release".
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla reported its Q1FY26 (quarter ended June 30, 2025) results with consolidated revenue from operations of INR 6,957 Cr, up 3.9% year-on-year. Profit after tax grew 10.2% YoY to INR 1,298 Cr, with margins expanding to 18.7%, while EBITDA stood at INR 1,778 Cr with a steady margin of 25.6%. The One-India business crossed the INR 3,000 Cr mark for the first time in any opening quarter, growing 6% YoY. North America revenue declined 7% YoY to INR 1,933 Cr (USD 226 Mn), though the company launched Nano Paclitaxel and Nilotinib capsules and signed a deal for its first U.S. biosimilar. Africa grew 11% in USD terms and Emerging Markets & Europe posted 8% USD growth. R&D spend was INR 432 Cr (6.2% of sales), and the company holds a strong net cash position of INR 10,379 Cr.
Steady overall performance with healthy PAT growth and a strong net cash balance sheet should support investor confidence, though the 7% decline in North America revenue may draw some attention. The upcoming U.S. biosimilar launch and continued momentum in India and emerging markets are positive forward-looking signals.